MM patients with t(11;14) translocations, who represents 15-20% of MM patients be more sensitive to venetoclax as they have high ratios of BCL-2/MCL-1 in their tumor cells (116, 117). This evidence concerns the gene BCL2 and Miyoshi myopathy.